» Articles » PMID: 33971821

Discovery and Validation of Novel Protein Markers in Mucosa of Portal Hypertensive Gastropathy

Overview
Publisher Biomed Central
Specialty Gastroenterology
Date 2021 May 11
PMID 33971821
Citations 1
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Portal hypertension induced esophageal and gastric variceal bleeding is the main cause of death among patients of decompensated liver cirrhosis. Therefore, a standardized, biomarker-based test, to make an early-stage non-invasive risk assessment of portal hypertension, is highly desirable. However, no fit-for-purpose biomarkers have yet been identified.

Methods: We conducted a pilot study consisting of 5 portal hypertensive gastropathy (PHG) patients and 5 normal controls, sampling the gastric mucosa of normal controls and PHG patients before and after endoscopic cyanoacrylate injection, using label-free quantitative (LFQ) mass spectrometry, to identify potential biomarker candidates in gastric mucosa from PHG patients and normal controls. Then we further used parallel reaction monitoring (PRM) to verify the abundance of the targeted protein.

Results: LFQ analyses identified 423 significantly differentially expressed proteins. 17 proteins that significantly elevated in the gastric mucosa of PHG patients were further validated using PRM.

Conclusions: This is the first application of an LFQ-PRM workflow to identify and validate PHG-specific biomarkers in patient gastric mucosa samples. Our findings lay the foundation for comprehending the molecular mechanisms of PHG pathogenesis, and provide potential applications for useful biomarkers in early diagnosis and treatment. Trial registration and ethics approval: Trial registration was completed (ChiCTR2000029840) on February 25, 2020. Ethics Approvals were completed on July 17, 2017 (NYSZYYEC20180003) and February 15, 2020 (NYSZYYEC20200005).

Citing Articles

Serum proteomic profiling of patients with compensated advanced chronic liver disease with and without clinically significant portal hypertension.

Pastrovic F, Novak R, Grgurevic I, Hrkac S, Salai G, Zarak M PLoS One. 2024; 19(4):e0301416.

PMID: 38603681 PMC: 11008873. DOI: 10.1371/journal.pone.0301416.

References
1.
Karp N, Huber W, Sadowski P, Charles P, Hester S, Lilley K . Addressing accuracy and precision issues in iTRAQ quantitation. Mol Cell Proteomics. 2010; 9(9):1885-97. PMC: 2938101. DOI: 10.1074/mcp.M900628-MCP200. View

2.
Karimi A, Milewicz D . Structure of the Elastin-Contractile Units in the Thoracic Aorta and How Genes That Cause Thoracic Aortic Aneurysms and Dissections Disrupt This Structure. Can J Cardiol. 2016; 32(1):26-34. PMC: 4839280. DOI: 10.1016/j.cjca.2015.11.004. View

3.
Wallner K, Sharifi B, Shah P, Noguchi S, DeLeon H, Wilcox J . Adventitial remodeling after angioplasty is associated with expression of tenascin mRNA by adventitial myofibroblasts. J Am Coll Cardiol. 2001; 37(2):655-61. DOI: 10.1016/s0735-1097(00)01117-7. View

4.
Zhang P, Zhu Y, Luo X, Zhou S . Comparative proteomic analysis provides insights into the complex responses to Pseudoperonospora cubensis infection of cucumber (Cucumis sativus L.). Sci Rep. 2019; 9(1):9433. PMC: 6603182. DOI: 10.1038/s41598-019-45111-4. View

5.
Bracht T, Schweinsberg V, Trippler M, Kohl M, Ahrens M, Padden J . Analysis of disease-associated protein expression using quantitative proteomics—fibulin-5 is expressed in association with hepatic fibrosis. J Proteome Res. 2015; 14(5):2278-86. DOI: 10.1021/acs.jproteome.5b00053. View